Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
House dust mite allergoid immunotherapy trial in allergic rhinitis/rhinoconjunctivitis
2009-014036-37Phase 3Terminated
- Sponsor
- Allergopharma
- Start
- Jan 2010
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy comparing House dust mite allergoid with Placebo (2 arms). Primary endpoint: Efficacy endpoint mentioned in detailed description. Started Jan 2010; status: terminated.
02
Drugs
Acaroid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2009-014036-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014036-37.